EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Use of 2,6-diaminopurine as a potent suppressor of UGA premature stop codons in cystic fibrosis

Catherine Leroy, Sacha Spelier, Nadège Charlene Essonghe, Virginie Poix, Rebekah Kong, Patrick Gizzi, Claire Bourban, Séverine Amand, Christine Bailly, Romain Guilbert, David Hannebique, Philippe Persoons und 11 weitere

Molecular Therapy · 2023-04 · 31 (4) · 970-985

DOI: 10.1016/j.ymthe.2023.01.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2023-04. Verfasst von Catherine Leroy und 22 weiteren Autor:innen. Beteiligte Einrichtung: University Lille, CNRS, INSERM, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, 59000 Lille, France; Unité Tumorig…. Hauptthemen laut MEDLINE: Codon, Nonsense, Cystic Fibrosis. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nonsense mutations are responsible for around 10% of cases of genetic diseases, including cystic fibrosis. 2,6-diaminopurine (DAP) has recently been shown to promote efficient readthrough of UGA premature stop codons. In this study, we show that DAP can correct a nonsense mutation in the Cftr gene in vivo in a new CF mouse model, in utero, and through breastfeeding, thanks, notably, to adequate pharmacokinetic properties. DAP turns out to be very stable in plasma and is distributed throughout the body. The ability of DAP to correct various endogenous UGA nonsense mutations in the CFTR gene and to restore its function in mice, in organoids derived from murine or patient cells, and in cells from patients with cystic fibrosis reveals the potential of such readthrough-stimulating molecules in developing a therapeutic approach. The fact that correction by DAP of certain nonsense mutations reaches a clinically relevant level, as judged from previous studies, makes the use of this compound all the more attractive.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Codon, NonsenseCystic FibrosisMiceAnimalsCodon, TerminatorCystic Fibrosis Transmembrane Conductance Regulator2-Aminopurine

Stichwörter der Autor:innen

2,6-diaminopurinecystic fibrosismouse modelnonsense mutationreadthrough molecule

Substanzen

Codon, NonsenseCodon, TerminatorCystic Fibrosis Transmembrane Conductance Regulator2,6-diaminopurine2-Aminopurine

Autor:innen und Institutionen

  • University Lille, CNRS, INSERM, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, 59000 Lille, France; Unité Tumorigenèse et Résistance aux Traitements, Institut Pasteur de Lille, 59000…
  • Pediatric Respiratory Medicine, Wilhelmina Children's Hospital, University Medical Center, Utrecht University, 3584 EA Utrecht, the Netherlands; Regenerative Medicine Utrecht, University Medical Center, Utrecht Universi…
  • University Lille, INSERM, U1003-PHYCEL-Physiologie Cellulaire, 59000 Lille, France; Laboratory of Excellence, Ion Channels Science and Therapeutics, 59655 Villeneuve d'Ascq, France.
  • Plateforme de Chimie Biologique Intégrative de Strasbourg, UAR 3286 CNRS-Université de Strasbourg, 67404 Illkirch, France.
  • Muséum National d'Histoire Naturelle, Centre National de la Recherche Scientifique, Laboratory of Molecules of Communication and Adaptation of Microorganisms (MCAM), UMR 7245 CNRS-MNHN, CP 54, 57 Rue Cuvier, 75005 Paris…
  • Institut Pasteur de Lille-PLEHTA (Plateforme d'Expérimentation et de Haute Technologie Animale), 59019 Lille, France.

Zitieren

APA

Leroy, C., Spelier, S., Essonghe, N. C., Poix, V., Kong, R., Gizzi, P., Bourban, C., Amand, S., Bailly, C., Guilbert, R., Hannebique, D., Persoons, P., Arhant, G., Prévotat, A., Reix, P., Hubert, D., Gérardin, M., Chamaillard, M., Prevarskaya, N., …, & Lejeune, F. (2023). Use of 2,6-diaminopurine as a potent suppressor of UGA premature stop codons in cystic fibrosis. Molecular Therapy, 31(4), 970-985. https://doi.org/10.1016/j.ymthe.2023.01.014

Vancouver

Leroy C, Spelier S, Essonghe NC, Poix V, Kong R, Gizzi P, et al. Use of 2,6-diaminopurine as a potent suppressor of UGA premature stop codons in cystic fibrosis. Molecular Therapy. 2023;31(4):970-985. doi:10.1016/j.ymthe.2023.01.014

BibTeX
@article{Leroy2023,
  author = {Leroy, Catherine and Spelier, Sacha and Essonghe, Nadège Charlene and Poix, Virginie and Kong, Rebekah and Gizzi, Patrick and Bourban, Claire and Amand, Séverine and Bailly, Christine and Guilbert, Romain and Hannebique, David and Persoons, Philippe and Arhant, Gwenaëlle and Prévotat, Anne and Reix, Philippe and Hubert, Dominique and Gérardin, Michèle and Chamaillard, Mathias and Prevarskaya, Natalia and Rebuffat, Sylvie and Shapovalov, George and Beekman, Jeffrey and Lejeune, Fabrice},
  title = {Use of 2,6-diaminopurine as a potent suppressor of UGA premature stop codons in cystic fibrosis},
  journal = {Molecular Therapy},
  year = {2023},
  volume = {31},
  number = {4},
  pages = {970--985},
  doi = {10.1016/j.ymthe.2023.01.014}
}
Kostenlos starten →